Table 1

Crude and adjusted NMOSD prevalence estimates by region, ancestry and overall

SubpopulationNMOSD casesPopulationLatitudeCrude prevalence†Adj prevalence‡
Clinical onlyClinical and laboratoryLaboratory only*Total(° South)(per 100 000)(per 100 000)
Region
 QLD/NT21226 (2)404 898 10025.09540.82 (0.56 to 1.08)0.95 (0.78 to 1.12)
 WA11462 517 20031.59060.24 (0.05 to 0.43)0.40 (0.00 to 0.89)
 NSW/ACT111727 (2)557 791 10033.53020.68 (0.50 to 0.86)0.93 (0.71 to 1.15)
 SA23271 670 80034.84740.37 (0.09 to 0.64)0.44 (0.24 to 0.63)
 VIC/TAS31013 (2)266 250 60038.08480.43 (0.24 to 0.62)0.56 (0.42 to 0.71)
 NZ696 (2)214 442 10038.15070.38 (0.23 to 0.53)0.47 (0.37 to 0.58)
Ancestry
 Asian61222403 259 0471.23 (0.85 to 1.61)1.57 (1.15 to 1.98)
 Other184156 (8)11524 410 8530.44 (0.36 to 0.52)0.57 (0.50 to 0.65)
Total25527815527 669 9000.65 (0.58 to 0.73)0.70 (0.61 to 0.78)
  • *Figures in parentheses indicate estimated numbers of missed seronegative cases added to the estimate.

  • †Excludes estimated numbers of missed seronegative cases, figures in parentheses indicate 95% CI.

  • ‡Adjusted using Lincoln-Peterson capture–recapture methodology, figures in parentheses indicate 95% CI.

  • ACT, Australian Capital Territory; Adj, adjusted; NMOSD, neuromyelitis optica spectrum disorder; NSW, New South Wales; NT, Northern Territory; NZ, New Zealand; QLD, Queensland; SA, South Australia; TAS, Tasmania; VIC, Victoria; WA, Western Australia.